Fig. 1: Analyses of human SLFN5 expression in BRCA using TCGA data, clinical samples and cell lines. | British Journal of Cancer

Fig. 1: Analyses of human SLFN5 expression in BRCA using TCGA data, clinical samples and cell lines.

From: Human Schlafen 5 regulates reversible epithelial and mesenchymal transitions in breast cancer by suppression of ZEB1 transcription

Fig. 1

a The processed TCGA breast cancer FPKM gene expression matrix was downloaded from the UCSC Xena platform (https://gdc.xenahubs.net), and clinical information for the corresponding samples was downloaded from TCGA (https://cancergenome.nih.gov). BRCA patients were divided into three groups: primary unmetastasised BRCA, lymphatic metastasised BRCA and distant metastasised BRCA. Differential expression analysis of SLFN5 RNA levels in normal controls and in local primary tumour tissues for each BRCA group. b Immunohistochemistry analysis of SLFN5 protein levels in adjacent normal breast tissues, local primary tumour tissues with distant metastasis (Distant-met) or without distant metastasis (un-met) of BRCA luminal A and triple-negative subtypes. SLFN5 expression scores were calculated based on the percentage of positive cells and the staining intensity (mean ± SD, n = 5). H&E staining was performed to identify pathological features of cancer. Scale bar: 100 μm. c WB analysis of SLFN5 expression in breast cancer cell lines. E-cadherin (E-cad) was used as an epithelial marker, vimentin was used as a mesenchymal marker and actin was used as a loading control. Protein band intensity was quantified using Quantity One software (Bio-Rad), and it is presented as the mean ± SD of three independent experiments. d Real-time PCR analysis of the mRNA levels of SLFN5, E-cadherin and vimentin in breast cancer cell lines.

Back to article page